Tuberous sclerosis with negative genetic testing and multiple cerebral cavernomas: A new association (Case report)

xlomafota13 shared this article with you from Inoreader Tuberous sclerosis with negative genetic testing and multiple cerebral cavernomas: A new association (Case report) Via Experimental and therapeutic medicine Exp Ther Med. 2021 Oct;22(4):1183. doi: 10.3892/etm.2021.10617. Epub 2021 Aug 16. ABSTRACT Tuberous sclerosis complex (TSC) is an autosomal dominant disorder with multisystemic involvement usually resulting from mutations in the tuberous sclerosis 1 (TSC1) or TSC2 genes. However, 10 to 25% of patients do not exhibit these mutations. Cerebral cavernous malformations (CCMs) are capillary-venous malformations that can be asymptomatic or cause variable neurological manifestations, including seizures. Familial CCMs are recognized. In both conditions, specific dermatological lesions are associated. We present the case of a 31-year-old female with TSC diagnosed at the age of 18 years who presented with negative genetic testing. She was admitted to our department in 2019 for a sudden increased frequency of focal seizures. Patient examination revealed multiple facial and intraoral angiofibroma, diplopia, right hemihypoesthesia, br isk deep tendon reflexes, and distal leg paresthesia. VideoEEG indicated a frontal paramedian epileptogenic focus. Cerebral magnetic resonance imaging (MRI) and angioMRI identified multiple fronto-parietal cortical tubers, as well as multiple CCMs, with evidence of bleeding in one. Under antiepileptic drug (AED) and mTOR inhibitor treatment, the seizure frequency significantly improved in a short period of time. This is the first reported case of tuberous sclerosis with negative genetic testing associated with multiple cerebral cavernoma. Such complex patients require multidisciplinary management and detailed genetic testing for increasing knowledge on neuro-cutaneous disorders. PMID:34475973 | PMC:PMC8406763 | DOI:10.3892/etm.2021.10617 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.